Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

  • Conferences
    • AACR26
    • AACR25
    • AACR24
    • AACR23
    • AACR22
    • AACR21
    • AACR20
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR EORTC Mol Targets
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO25
    • ASCO24
    • ASCO23
    • ASCO22
    • ASCO21
    • ASCO20
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH25
    • ASH24
    • ASH23
    • ASH22
    • ASH21
    • ASH20
    • ASH19
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • EHA iCML
    • ESMO25
    • ESMO24
    • ESMO23
    • ESMO22
    • ESMO21
    • ESMO20
    • ESMO19
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM22
    • JPM20
    • SABCS
    • SITC25
    • SITC 2024
    • SITC 2023
    • SITC 2022
    • SITC 2021
    • SITC 2020
    • SITC 2019
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
  • Targets
    • ADC
    • Adenosine
    • AI & ML
    • Autoimmune
    • Bispecifics / Trispecifics
    • Cytokines
    • DDR
    • Epigenetics
    • gamma delta T cells
    • MYC
    • Neoantigens
    • NK Cells
    • RAS
    • SERDs
    • STING
    • TIGIT
    • TLRs
  • About
  • Contact
  • Pricing
  • Immuno-Oncology
  • Protein Degraders
  • Cell Therapy
  • Interviews
  • ASCO26
  • Premium Content
  • Login

  • Cat amongst the pigeons

    Read more

  • Reflections on potentially practice changing trials

    Read more

  • What if the first target was the problem?

    Read more

  • Late line RCC: where darlifarnib fits and why LITESPARK-012 matters

    Read more

  • The goalposts shifted in Berlin, your trial timeline didn’t

    Read more

  • Pointed ironies: SERD wars, ADC hype, and what really works in breast cancer

    Read more

  • A study in regulatory conservatism versus clinical innovation

    Read more

  • What your CD3 T cell engager is missing

    Read more
E

Cat amongst the pigeons

Is there a reckoning coming in the ADC space? All evidence points to a shake up

View post
E

Reflections on potentially practice changing trials

20 phase 3 trials at ASCO and W2W4

View post
E

What if the first target was the problem?

A look at Pheast Therapeutics emerging antibody and ADC pipeline

View post

Terms of Use & Privacy Policy
Copyright © 2010-26 Biotech Strategy Blog

error: Content is protected !!